Евразийские клинические рекомендации по диагностике и лечению желудочковых нарушений ритма сердца и профилактике внезапной сердечной смерти (2022)

Евразийские клинические рекомендации по диагностике и лечению желудочковых нарушений ритма сердца и профилактике внезапной сердечной смерти (2022)

Автор: Голицын С.П., Костюкевич М.В., Лайович Л.Ю., Миронов Н.Ю., Миронова Н.А., Уцумуева М.Д., Хусяинова Д.Р., Шлевков Н.Б., Базаров Б.Ч., Азизов В.А., Джишамбаев Э.Д., Закиров Н.У., Гончарик Д.Б.

Журнал: Евразийский кардиологический журнал @eurasian-cardiology-journal

Рубрика: Клинические рекомендации

Статья в выпуске: 4, 2022 года.

Бесплатный доступ

Рекомендации ЕАК отражают точку зрения ЕАК и были подготовлены после тщательного изучения научных и медицинских данных, имеющихся на момент их публикации. ЕАК не несут ответственности в случае какого-либо противоречия, несоответствия и / или неоднозначности между Рекомендациями ЕАК и любыми другими официальными рекомендациями или руководствами, выпущенными соответствующими органами общественного здравоохранения, в частности, в отношении правильного использования медицинских или терапевтических стратегий. Медицинским работникам рекомендуется в полной мере учитывать Рекомендации ЕАК при оценке своего клинического суждения, а также при определении и реализации профилактических, диагностических или терапевтических медицинских стратегий. Тем не менее, Рекомендации ЕАК никоим образом не отменяют индивидуальную ответственность медицинских работников за принятие надлежащих и точных решений с учетом состояния здоровья каждого пациента и в консультации с этим пациентом и, при необходимости и / или необходимости, опекуна пациента. Рекомендации ЕАК не освобождают медицинских работников от полного и тщательного рассмотрения соответствующих официальных обновленных рекомендаций или руководств, выпущенных компетентными органами общественного здравоохранения, для рассмотрения каждого медицинского случая в свете современных научно обоснованных рекомендаций в соответствии с их этическими и профессиональными обязательствами. Кроме того, медицинский работник обязан проверять действующие правила и положения, касающиеся лекарств и медицинских изделий, на момент назначения по рецепту.

Еще

Желудочковая тахикардия, фибрилляция желудочков, желудочковая экстрасистолия, внезапная смерть, нарушения ритма сердца, каналопатии, кардиомиопатии, клинические рекомендации

Короткий адрес: https://sciup.org/143179493

IDR: 143179493   |   DOI: 10.38109/2225-1685-2022-4-6-67

Список литературы Евразийские клинические рекомендации по диагностике и лечению желудочковых нарушений ритма сердца и профилактике внезапной сердечной смерти (2022)

  • “Министерство здравоохранения Российской Федерации. Клинические рекомендации. Дата доступа 02/06/2021г.” https://scardio.ru/content/Guidelines/2020/Clinic_rekom_FP_TP-unlocked.pdf
  • Ревишвили А.Ш., Неминующий Н.М., Баталов Р.Е., Гиляров М.Ю., Голицын С.П., Давтян К.В., Думпис Я.Ю., Диденко М.В., Зенин С.А., Иваницкий Э.А., Комолятова В.Н., Кравцова Л.А.,Криволапов С.Н., Кузовлев А.Н., Купцов В.В., Лебедев Д.С., Линчак Р.М., Ломидзе Н, “Всероссийские клинические рекомендации по контролю над риском внезапной остановки сердца и внезапной сердечной смерти, профилактике и оказанию первой помощи,” Вестник аритмологии, vol. 89, pp. 2-104, 2017.
  • S. G. Priori et al., “2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Addenda,” Eur. Heart J., vol. 36, no. 41, pp. 2793-867, 2015, https://doi.org/10.1093/eurheartj/ehv316.
  • S. M. Al-Khatib et al., “2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society,” J. Am. Coll. Cardiol., vol. 72, no. 14, 2018, https://doi.org/10.1016/j.jacc.2017.10.054.
  • E. M. Cronin et al., “2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias,” Hear. Rhythm, vol. 17, no. 1, 2020, https://doi.org/10.1016/j.hrthm.2019.03.002.
  • M. J. Ackerman et al., “HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA),” Hear. Rhythm, vol. 8, no. 8, 2011, https://doi.org/10.1016/j.hrthm.2011.05.020.
  • M. N. Niemeijer et al., “Declining incidence of sudden cardiac death from 1990-2010 in a general middle-aged and elderly population: The Rotterdam Study,” Hear. Rhythm, vol. 12, no. 1, 2015, https://doi.org/10.1016/j.hrthm.2014.09.054.
  • S. Mendis, P. Puska, and B. Norrving, “Global atlas on cardiovascular disease prevention and control,” World Heal. Organ., pp. 2-14, 2011, https://doi.org/NLM classification: WG 120.
  • R. E. Eckart et al., “Sudden death in young adults: An autopsy-based series of a population undergoing active surveillance,” J. Am. Coll. Cardiol., vol. 58, no. 12, 2011, https://doi.org/10.1016/j.jacc.2011.01.049.
  • B. J. Maron, T. E. Gohman, and D. Aeppli, “Prevalence of sudden cardiac death during competitive sports activities in Minnesota high school athletes,” J. Am. Coll. Cardiol., vol. 32, no. 7, 1998, https://doi.org/10.1016/S0735-1097(98)00491-4.
  • C. Van Der Werf et al., “Improving usual care after sudden death in the young with focus on inherited cardiac diseases (the CAREFUL study): A community-based intervention study,” Europace, vol. 18, no. 4, 2016, https://doi.org/10.1093/europace/euv059.
  • “United Nations Economic Commission for Europe. UNECE statistical database. http://w3.unece.org/pxweb. Дата доступа 01/02/2021”.
  • “AHA Statistical Update Heart Disease and Stroke Statistics - 2019 Update A Report From the American Heart Association. https://doi.org/10.1161/CIR.0000000000000659. Circulation. 2019;139:e56-e528”.
  • Макаров Л.М., Комолятова В.Н., Киселева И.И., Солохин Ю.А., “Распространённость внезапной сердечной смерти у лиц молодого возраста в крупном мегаполисе медицинский алфавит.,” Кардиология, vol. 1, pp. 35-40.
  • Щербакова Н.В., Воинова В.Ю., Школьникова М.А., “Генетика и сердце: основания для внедрения генетического тестирования в клиническую практику. Педиатрия.,” Журнал им. Г.Н. Сперанского., vol. 99, no. 3, pp. 8-15, 2020, https://doi.org/10.24110/0031-403X-2020-99-3-8-15.
  • B. J. Maron, J. J. Doerer, T. S. Haas, D. M. Tierney, and F. O. Mueller, “Sudden deaths in young competitive athletes analysis of 1866 deaths in the united states, 1980-2006,” Circulation, vol. 119, no. 8, 2009, https://doi.org/10.1161/CIRCULATIONAHA.108.804617.
  • Рытова А.И., Хлебус Э.Ю., Шевцов А.Е., Куценко В.А., Щербакова Н.В., Жарикова А.А., Ершова А.И., Киселева А.В., Бойцов С.А., Яровая Е.Б., Мешков А.Н., “Современные вероятностно-статистические подходы к поиску вариантов нуклеотидной последовательности, ассоциированных с комплексными заболеваниями.,” Генетика, vol. 53, no. 10, pp. 1153-1169, 2017, https://doi.org/10.7868/S0016675817100083.
  • Воинова В.Ю., Николаева Е.А., Щербакова Н.В., Яблонская М.И., “Высокопроизводительное секвенирование днк для идентификации генетически детерминированных заболеваний в педиатрической практике.,” Российский вестник перинатологии и педиатрии, vol. 64, no. 1, pp. 103-109, 2019, https://doi.org/10.21508/1027-4065-2019-64-1-103-109.
  • R. Puranik, C. K. Chow, J. A. Duflou, M. J. Kilborn, and M. A. McGuire, “Sudden death in the young.,” Hear. Rhythm, vol. 2, no. 12, pp. 1277- 1282, Dec. 2005, https://doi.org/10.1016/j.hrthm.2005.09.008.
  • R. E. Eckart et al., “Sudden death in young adults: A 25-year review of autopsies in military recruits,” Annals of Internal Medicine, vol. 141, no. 11. 2004. https://doi.org/10.7326/0003-4819-141-11-200412070-00005.
  • Щербакова Н.В., Жиронкина А.Б., Воинова В.Ю., Ильдарова Р.А., Школьникова М.А., “Фенотипическая вариабельность и варианты-модификаторы у детей с наследственными заболеваниями сердца.,” Российский вестник перинатологии и педиатрии., vol. 66, no. 3, pp. 12-19, 2021, https://doi.org/10.21508/1027-4065-2021-66-3-12-19.
  • B. G. Winkel et al., “Nationwide study of sudden cardiac death in persons aged 1-35 years,” Eur. Heart J., vol. 32, no. 8, 2011, https://doi.org/10.1093/eurheartj/ehq428.
  • B. Risgaard et al., “Burden of sudden cardiac death in persons aged 1 to 49 years nationwide study in denmark,” Circ. Arrhythmia Electrophysiol., vol. 7, no. 2, 2014, https://doi.org/10.1161/CIRCEP.113.001421.
  • S. V. De Noronha et al., “The importance of specialist cardiac histopathological examination in the investigation of young sudden cardiac deaths,” Europace, vol. 16, no. 6, 2014, https://doi.org/10.1093/europace/eut329.
  • Shcherbakova N., Kulikova O., Myasnikov R., Kiseleva A., Kharlap M., Meshkov A., Mershina E., Sinitsyn V., Boytsov S., “The genetics of noncompaction cardiomyopathy,” Eur. J. Hear. Fail. Suppl., vol. 19, no. S1, p. 437, 2017.
  • Б. С. А. Мясников Р.П., Щербакова Н.В., Куликова О.В., Мешков А.Н., Харлап М.С., Киселева А.В., Жарикова А.А., Дадали Е.Л., Семенова Н.А., Корецкий С.Н., Благова О.В., Мершина Е.А., Синицын В.Е., Драпкина О.М., “Мутация гена DES в семье пробанда с миофибриллярной миопатией и развитием некомпактной кардиомиопатии, приведшей к трансплантации сердца.,” Российский кардиологический журнал., vol. 22, no. 10, pp. 9-16, 2017, https://doi.org/10.15829/1560-4071-2017-10-9-16.
  • M. P. Suárez-Mier, B. Aguilera, R. M. Mosquera, and M. S. Sánchezde-León, “Pathology of sudden death during recreational sports in Spain,” Forensic Sci. Int., vol. 226, no. 1-3, 2013, https://doi.org/10.1016/j.forsciint.2013.01.016.
  • A. Mazzanti et al., “The usual suspects in sudden cardiac death of the young: A focus on inherited arrhythmogenic diseases,” Expert Review of Cardiovascular Therapy, vol. 12, no. 4. 2014. https://doi.org/10.1586/14779072.2014.894884.
  • Хидирова Л.Д., Яхонтов Д.А., Зенин С.А., “Особенности течения фибрилляции предсердий у пациентов с коморбидностью в зависимости от проводимой терапии.,” Комплексные проблемы сердечно-сосудистых заболеваний., vol. 8, no. 2, pp. 21-29, 2019, https://doi.org/10.17802/2306-1278-2019-8-2-21-29.
  • J. Lu et al., “Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a populationbased screening study (China PEACE Million Persons Project),” Lancet, vol. 390, no. 10112, 2017, https://doi.org/10.1016/S0140-6736(17)32478-9.
  • R. B. Schnabel et al., “50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: A cohort study,” Lancet, vol. 386, no. 9989, 2015, https://doi.org/10.1016/S0140-6736(14)61774-8.
  • M. A. Shkolnikova et al., “Atrial fibrillation among Russian men and women aged 55 years and older: Prevalence, mortality, and associations with biomarkers in a population-based study,” J. Geriatr. Cardiol., vol. 17, no. 2, 2020, https://doi.org/10.11909/j.issn.1671-5411.2020.02.002.
  • B. Ziaeian and G. C. Fonarow, “Epidemiology and aetiology of heart failure,” Nature Reviews Cardiology, vol. 13, no. 6. 2016. https://doi.org/10.1038/nrcardio.2016.25.
  • Акрамова Э.Г., “Проблемы диагностики коморбидных форм хронической обструктивной болезни легких.,” Научное обозрение. Медицинские науки., vol. 3, pp. 5-22, 2016.
  • Акрамова Э.Г., Стручков П.В., Хамитов Р.Ф., Бакиров Р.С., “Электро и эхокардиографические признаки легочного сердца у больных хронической обструктивной болезнью легких с сопутствующей артериальной гипертензией.,” Пульмонология., vol. 4, pp. 46-51, 2013.
  • Хидирова Л.Д., Яхонтов Д.А., Зенин С.А., “Гипертоническая болезнь в сочетании с фибрилляцией предсердий и экстракардиальными заболеваниями.,” Казанский медицинский журнал, vol. 99, no. 6, pp. 894-899, 2018, https://doi.org/10.17816/KMJ2018-894.
  • Мешков А.Н., Ершова А.И., Щербакова Н.В., Рожкова Т.А., Калинина М.В., Кухарчук В.В., Бойцов С.А., “Фенотипические особенности течения гетерозиготной формы семейной гиперхолестеринемии у носителей мутаций генов LDLR и APOB,” Кардиоваскулярная терапия и профилактика, vol. 10, no. 8, pp. 63-65, 2011.
  • Близнюк С.А., Рожкова Т.А., Ежов М.В., Попова А.Б., Малахов В.В., Трипотень М.И., Погорелова О.А., Чубыкина У.В., Тмоян Н.А., Балахонова Т.В., Афанасьева М.И., Афанасьева О.И., Покровский С.Н., “Особенности гиполипидемической терапии и предикторы сердечно-сосудистых осложнений у больных с гетерозиготной семейной гиперхолестеринемией.,” Атеросклероз и дислипидемии, vol. 4, no. 37, pp. 36-45, 2019, https://doi.org/10.34687/2219-8202.JAD.2019.04.0004.
  • Курбанисмаилова П.М., Попова А.Б., Драненко Н.Ю., Сергиенко И.В., “Проблема выявления пациентов с семейной гиперхолестеринемией.,” Клиническая практика, vol. 3, no. 31, pp. 61-69, 2017.
  • R. McPherson and A. Tybjaerg-Hansen, “Genetics of Coronary Artery Disease,” Circ. Res., vol. 118, no. 4, 2016, https://doi.org/10.1161/CIRCRESAHA.115.306566.
  • Щербакова Н.В., Мешков А.Н., Бойцов С.А., “Применение метода секвенирования экзомов для диагностики предрасположенности к комплексным заболеваниям в профилактической медицине.,” Кардиоваскулярная терапия и профилактика, vol. 12, no. 6, pp. 24-28, 2013.
  • Мешков А.Н., Калинина М.В., Ершова А.И., Косенков Е.И., Щербакова Н.В., Рожкова Т.А., Масенко В.П., Кухарчук В.В., Бойцов С.А., “Уровень PCSK9 в семьях пациентов с семейной гиперхолестеринемией.,” Атеросклероз и дислипидемии, vol. 1, no. 6, pp. 12-15, 2012.
  • C. Basso et al., “Guidelines for autopsy investigation of sudden cardiac death,” Virchows Archiv, vol. 452, no. 1. 2008. https://doi.org/10.1007/s00428-007-0505-5.
  • C. Basso, E. Carturan, K. Pilichou, S. Rizzo, D. Corrado, and G. Thiene, “Sudden cardiac death with normal heart: Molecular autopsy,” in Cardiovascular Pathology, 2010, vol. 19, no. 6. https://doi.org/10.1016/j.carpath.2010.02.003.
  • D. J. Tester, A. Medeiros-Domingo, M. L. Will, C. M. Haglund, and M. J. Ackerman, “Cardiac channel molecular autopsy: Insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing,” in Mayo Clinic Proceedings, 2012, vol. 87, no. 6. https://doi.org/10.1016/j.mayocp.2012.02.017.
  • S. G. Priori et al., “Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes.,” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, vol. 15, no. 10. 2013. https://doi.org/10.1093/europace/eut272.
  • A. Moya et al., “Guidelines for the diagnosis and management of syncope (version 2009),” European Heart Journal, vol. 30, no. 21. 2009. https://doi.org/10.1093/eurheartj/ehp298.
  • X. Jouven, M. Desnos, C. Guerot, and P. Ducimetière, “Predicting sudden death in the population. The Paris prospective study I,” Circulation, vol. 99, no. 15, 1999, https://doi.org/10.1161/01.CIR.99.15.1978.
  • Y. Friedlander et al., “Family history as a risk factor for primary cardiac arrest,” Circulation, vol. 97, no. 2, 1998, https://doi.org/10.1161/01.CIR.97.2.155.
  • D. P. Zipes et al., “ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/ American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines,” Europace, vol. 8, no. 9. 2006. https://doi.org/10.1093/europace/eul108.
  • S. George, I. Rodriguez, D. Ipe, P. T. Sager, I. Gussak, and B. Vajdic, “Computerized extraction of electrocardiograms from continuous 12-lead holter recordings reduces measurement variability in a thorough QT study,” J. Clin. Pharmacol., vol. 52, no. 12, 2012, https://doi.org/10.1177/0091270011430505.
  • C. De Asmundis et al., “Comparison of the patient-activated event recording system vs. traditional 24 h Holter electrocardiography in individuals with paroxysmal palpitations or dizziness,” Europace, vol. 16, no. 8, 2014, https://doi.org/10.1093/europace/eut411.
  • K. Volosin, R. W. Stadler, R. Wyszynski, and P. Kirchhof, “Tachycardia detection performance of implantable loop recorders: Results from a large ‘real-life’ patient cohort and patients with induced ventricular arrhythmias,” Europace, vol. 15, no. 8, 2013, https://doi.org/10.1093/europace/eut036.
  • G. S. Kamath et al., “Value of the signal-averaged electrocardiogram in arrhythmogenic right ventricular cardiomyopathy/dysplasia,” Hear. Rhythm, vol. 8, no. 2, 2011, https://doi.org/10.1016/j.hrthm.2010.10.007.
  • A. Nava et al., “Signal-averaged electrocardiogram in patients with arrhythmogenic right ventricular cardiomyopathy and ventricular arrhythmias,” Eur. Heart J., vol. 21, no. 1, 2000, https://doi.org/10.1053/euhj.1999.1733.
  • R. J. Gibbons et al., “ACC/AHA 2002 guideline update for exercise testing: Summary article. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to update the 1997 exercise testing guidelines),” Circulation, vol. 106, no. 14. 2002. https://doi.org/10.1161/01.CIR.0000034670.06526.15.
  • P. J. Podrid and T. B. Graboys, “Exercise stress testing in the management of cardiac rhythm disorders,” Med. Clin. North Am., vol. 68, no. 5, 1984, https://doi.org/10.1016/S0025-7125(16)31089-6.
  • D. P. Zipes et al., “ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines.,” European Heart Journal, vol. 27, no. 17. 2006. https://doi.org/10.1093/eurheartj/ehl199.
  • M. Prastaro et al., “Prognostic role of transthoracic echocardiography in patients affected by heart failure and reduced ejection fraction,” Heart Fail. Rev., vol. 20, no. 3, 2015, https://doi.org/10.1007/s10741-014-9461-8.
  • D. T. Chiu, N. I. Shapiro, B. C. Sun, J. L. Mottley, and S. A. Grossman, “Are echocardiography, telemetry, ambulatory electrocardiography monitoring, and cardiac enzymes in emergency department patients presenting with syncope useful tests? A preliminary investigation,” J. Emerg. Med., vol. 47, no. 1, 2014, https://doi.org/10.1016/j.jemermed.2014.01.018.
  • M. J. Zellweger et al., “Threshold, incidence, and predictors of prognostically high-risk silent ischemia in asymptomatic patients without prior diagnosis of coronary artery disease,” J. Nucl. Cardiol., vol. 16, no. 2, 2009, https://doi.org/10.1007/s12350-008-9016-2.
  • X. Kang et al., “Comparative ability of myocardial perfusion singlephoton emission computed tomography to detect coronary artery disease in patients with and without diabetes mellitus,” Am. Heart J., vol. 137, no. 5, 1999, https://doi.org/10.1016/S0002-8703(99)70421-7.
  • J. E. Marine et al., “Prevalence and prognostic significance of exerciseinduced nonsustained ventricular tachycardia in asymptomatic volunteers: BLSA (Baltimore Longitudinal Study of Aging),” J. Am. Coll. Cardiol., vol. 62, no. 7, 2013, https://doi.org/10.1016/j.jacc.2013.05.026.
  • M. D. Cheitlin et al., “ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography),” Circulation, vol. 108, no. 9. 2003. https://doi.org/10.1161/01.CIR.0000073597.57414.A9.
  • A. Zeliaś, J. Stȩpińska, J. Andres, A. Tra̧bka-Zawicki, J. Sadowski, and K. Zmudka, “Ten-year experience of an invasive cardiology centre with out-of-hospital cardiac arrest patients admitted for urgent coronary angiography,” Kardiol. Pol., vol. 72, no. 8, 2014, https://doi.org/10.5603/KP.a2014.0088.
  • S. Zaman et al., “Significance of repeat programmed ventricular stimulation at electrophysiology study for arrhythmia prediction after acute myocardial infarction,” PACE - Pacing Clin. Electrophysiol., vol. 37, no. 7, 2014, https://doi.org/10.1111/pace.12391.
  • B. Brembilla-Perrot, C. Suty-Selton, P. Houriez, O. Claudon, D. Beurrier, and A. T. De La Chaise, “Value of non-invasive and invasive studies in patients with bundle branch block, syncope and history of myocardial infarction,” Europace, vol. 3, no. 3, 2001, https://doi.org/10.1053/eupc.2001.0174.
  • A. Roguin et al., “Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy,” J. Am. Coll. Cardiol., vol. 43, no. 10, 2004, https://doi.org/10.1016/j.jacc.2004.01.030.
  • A. Bhonsale et al., “Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention,” J. Am. Coll. Cardiol., vol. 58, no. 14, 2011, https://doi.org/10.1016/j.jacc.2011.06.043.
  • J. J. Goldberger, H. Subačius, T. Patel, R. Cunnane, and A. H. Kadish, “Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy,” J. Am. Coll. Cardiol., vol. 63, no. 18, 2014, https://doi.org/10.1016/j.jacc.2013.12.021.
  • J. Brugada, R. Brugada, and P. Brugada, “Determinants of Sudden Cardiac Death in Individuals with the Electrocardiographic Pattern of Brugada Syndrome and No Previous Cardiac Arrest,” Circulation, vol. 108, no. 25, 2003, https://doi.org/10.1161/01.CIR.0000104568.13957.4F.
  • P. M. Elliott et al., “European Society of Cardiology Guidelines on diagnosis and management of hypertrophic cardiomyopathy,” Eur. Heart J., vol. 35, no. 39, 2014.
  • A. K. Bhandari, W. A. Shapiro, F. Morady, E. N. Shen, J. Mason, and M. M. Scheinman, “Electrophysiologic testing in patients with the long QT syndrome,” Circulation, vol. 71, no. 1, 1985, https://doi.org/10.1161/01.CIR.71.1.63.
  • C. Giustetto et al., “Long-term follow-up of patients with short QT syndrome,” J. Am. Coll. Cardiol., vol. 58, no. 6, 2011, https://doi.org/10.1016/j.jacc.2011.03.038.
  • A. Mazzanti et al., “Novel insight into the natural history of short QT syndrome,” J. Am. Coll. Cardiol., vol. 63, no. 13, 2014, https://doi.org/10.1016/j.jacc.2013.09.078.
  • P. Denes, E. Uretz, M. D. Ezri, and J. Borbola, “Clinical predictors of electrophysiologic findings in patients with syncope of unknown origin,” Arch. Intern. Med., vol. 148, no. 9, 1988, https://doi.org/10.1001/archinte.148.9.1922.
  • M. Brignole et al., “Mechanism of syncope in patients with bundle branch block and negative electrophysiological test,” Circulation, vol. 104, no. 17, 2001, https://doi.org/10.1161/hc4201.097837.
  • H. R. Middlekauff, W. G. Stevenson, L. W. Stevenson, and L. A. Saxon, “Syncope in advanced heart failure: High risk of sudden death regardless of origin of syncope,” J. Am. Coll. Cardiol., vol. 21, no. 1, 1993, https://doi.org/10.1016/0735-1097(93)90724-F.
  • H. J. J. Wellens et al., “Risk stratification for sudden cardiac death: Current status and challenges for the future,” Eur. Heart J., vol. 35, no. 25, 2014, https://doi.org/10.1093/eurheartj/ehu176.
  • M. Yoshinaga et al., “Electrocardiographic screening of 1-monthold infants for identifying prolonged QT intervals,” Circ. Arrhythmia Electrophysiol., vol. 6, no. 5, 2013, https://doi.org/10.1161/CIRCEP.113.000619.
  • M. Yoshinaga et al., “Genetic characteristics of children and adolescents with long-QT syndrome diagnosed by school-based electrocardiographic screening programs,” Circ. Arrhythmia Electrophysiol., vol. 7, no. 1, 2014, https://doi.org/10.1161/CIRCEP.113.000426.
  • P. J. Schwartz et al., “Prevalence of the congenital long-QT syndrome.,” Circulation, vol. 120, no. 18, pp. 1761-1767, Nov. 2009, https://doi.org/10.1161/CIRCULATIONAHA.109.863209.
  • D. Corrado et al., “Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol,” Eur. Heart J., vol. 26, no. 5, 2005, https://doi.org/10.1093/eurheartj/ehi108.
  • B. J. Maron et al., “Recommendations and Considerations Related to Preparticipation Screening for Cardiovascular Abnormalities in Competitive Athletes: 2007 Update,” Circulation, vol. 115, no. 12, 2007, https://doi.org/10.1161/circulationaha.107.181423.
  • A. Ljungqvist et al., “The International Olympic Committee (IOC) consensus statement on periodic health evaluation of elite athletes,” Int. Sport. J., vol. 10, no. 3, 2009.
  • A. Steinvil et al., “Mandatory electrocardiographic screening of athletes to reduce their risk for sudden death: Proven fact or wishful thinking?,” J. Am. Coll. Cardiol., vol. 57, no. 11, 2011, https://doi.org/10.1016/j.jacc.2010.10.037.
  • P. M. Narain R, Dhutia H, Merghani A, Myers J, MathotraA, Mitlar L, Sheikh N, Sharma S, “Featured Oral Abstracts. Preventing sudden cardiac death in the young: results from a population-based screening program in the UK,” Eur. J. Prev. Cardiol., vol. 21, no. 1_suppl, pp. S1-S6, May 2014, https://doi.org/10.1177/2047487314534570.
  • J. R. Kaltman et al., “Screening for sudden cardiac death in the young: Report from a national heart, lung, and blood institute working group,” Circulation, vol. 123, no. 17, 2011, https://doi.org/10.1161/CIRCULATIONAHA.110.017228.
  • C. A. James et al., “Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/ cardiomyopathy-associated desmosomal mutation carriers,” J. Am. Coll. Cardiol., vol. 62, no. 14, 2013, https://doi.org/10.1016/j.jacc.2013.06.033.
  • A. C. Sawant et al., “Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/ cardiomyopathy in patients without desmosomal mutations,” J. Am. Heart Assoc., vol. 3, no. 6, 2014, https://doi.org/10.1161/JAHA.114.001471.
  • G. Webster, T. Carberry, and S. Berger, “Screening for prevention of sudden death in the young: What is new?,” Current Opinion in Cardiology, vol. 35, no. 1. 2020. https://doi.org/10.1097/HCO.0000000000000689.
  • “приказ Министерства здравоохранения Российской Федерации от 3 февраля 2015 г. No 36ан «Об утверждении порядка проведения диспансеризации определенных групп взрослого населения»”.
  • “Приложение №1 к приказу Министерству здравоохранения Российской Федерации от 21 декабря 2012 г. N 1346н «О порядке прохождения несовершеннолетними медицинских осмотров, в том числе при поступлении в образовательные учреждения и в период обучения в них»”.
  • E. R. Behr et al., “Sudden arrhythmic death syndrome: Familial evaluation identifies inheritable heart disease in the majority of families,” Eur. Heart J., vol. 29, no. 13, 2008, https://doi.org/10.1093/eurheartj/ehn219.
  • P. Charron et al., “Genetic counselling and testing in cardiomyopathies: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases,” European Heart Journal, vol. 31, no. 22. 2010. https://doi.org/10.1093/eurheartj/ehq271.
  • I. Christiaans, E. Birnie, G. J. Bonsel, A. A. M. Wilde, and I. M. van Langen, “Uptake of genetic counselling and predictive DNA testing in hypertrophic cardiomyopathy,” Eur. J. Hum. Genet., vol. 16, no. 10, 2008, https://doi.org/10.1038/ejhg.2008.92.
  • E. Ormondroyd, S. Oates, M. Parker, E. Blair, and H. Watkins, “Presymptomatic genetic testing for inherited cardiac conditions: A qualitative exploration of psychosocial and ethical implications,” Eur. J. Hum. Genet., vol. 22, no. 1, 2014, https://doi.org/10.1038/ejhg.2013.81.
  • J. Ingles et al., “Health status of cardiac genetic disease patients and their at-risk relatives,” Int. J. Cardiol., vol. 165, no. 3, 2013, https://doi.org/10.1016/j.ijcard.2011.08.083.
  • R. N. Battista, I. Blancquaert, A. M. Laberge, N. Van Schendel, and N. Leduc, “Genetics in health care: An overview of current and emerging models,” Public Health Genomics, vol. 15, no. 1, 2011, https://doi.org/10.1159/000328846.
  • J. Ingles, J. M. Lind, P. Phongsavan, and C. Semsarian, “Psychosocial impact of specialized cardiac genetic clinics for hypertrophic cardiomyopathy,” Genet. Med., vol. 10, no. 2, 2008, https://doi.org/10.1097/GIM.0b013e3181612cc7.
  • I. Christiaans, I. M. Van Langen, E. Birnie, G. J. Bonsel, A. A. M. Wilde, and E. M. A. Smets, “Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: A cross-sectional cohort study,” Am. J. Med. Genet. Part A, vol. 149, no. 4, 2009, https://doi.org/10.1002/ajmg.a.32710.
  • C. McGorrian et al., “Family-based cardiac screening in relatives of victims of sudden arrhythmic death syndrome,” Europace, vol. 15, no. 7, 2013, https://doi.org/10.1093/europace/eus408.
  • R. J. Myerburg, K. M. Kessler, and A. Castellanos, “Sudden cardiac death: Structure, function, and time-dependence of risk,” in Circulation, 1992, vol. 85, no. 1 SUPPL.
  • D. M. Lloyd-Jones et al., “Framingham risk score and prediction of lifetime risk for coronary heart disease,” Am. J. Cardiol., vol. 94, no. 1, 2004, https://doi.org/10.1016/j.amjcard.2004.03.023.
  • J. Perk et al., “European guidelines on cardiovascular disease prevention in clinical practice (version 2012): The fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts),” International Journal of Behavioral Medicine, vol. 19, no. 4. 2012. https://doi.org/10.1007/s12529-012-9242-5.
  • L. R. C. Dekker et al., “Familial sudden death is an important risk factor for primary ventricular fibrillation: A case-control study in acute myocardial infarction patients,” Circulation, vol. 114, no. 11, 2006, https://doi.org/10.1161/CIRCULATIONAHA.105.606145.
  • D. G. Dechering et al., “Electrophysiological characteristics of ventricular tachyarrhythmias in cardiac sarcoidosis versus arrhythmogenic right ventricular cardiomyopathy,” Hear. Rhythm, vol. 10, no. 2, 2013, https://doi.org/10.1016/j.hrthm.2012.10.019.
  • C. R. Bezzina et al., “Genome-wide association study identifies a susceptibility locus at 21q21 for ventricular fibrillation in acute myocardial infarction,” Nat. Genet., vol. 42, no. 8, 2010, https://doi.org/10.1038/ng.623.
  • D. E. Arking et al., “Identification of a sudden cardiac death susceptibility locus at 2q24.2 through genome-wide association in european ancestry individuals,” PLoS Genet., vol. 7, no. 6, 2011, https://doi.org/10.1371/journal.pgen.1002158.
  • A. J. Moss et al., “Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.,” N. Engl. J. Med., vol. 346, no. 12, pp. 877-883, Mar. 2002, https://doi.org/10.1056/NEJMoa013474.
  • G. H. Bardy et al., “Amiodarone or an implantable cardioverterdefibrillator for congestive heart failure.,” N. Engl. J. Med., vol. 352, no. 3, pp. 225-237, Jan. 2005, https://doi.org/10.1056/NEJMoa043399.
  • P. A. Scott, J. Barry, P. R. Roberts, and J. M. Morgan, “Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: A meta-analysis,” Eur. J. Heart Fail., vol. 11, no. 10, 2009, https://doi.org/10.1093/eurjhf/hfp123.
  • Y. C. Levine et al., “B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias,” Hear. Rhythm, vol. 11, no. 7, 2014, https://doi.org/10.1016/j.hrthm.2014.04.024.
  • S. G. Priori et al., “Risk Stratification in the Long-QT Syndrome,” N. Engl. J. Med., vol. 348, no. 19, 2003, https://doi.org/10.1056/nejmoa022147.
  • P. Spirito, P. Bellone, K. M. Harris, P. Bernabò, P. Bruzzi, and B. J. Maron, “Magnitude of Left Ventricular Hypertrophy and Risk of Sudden Death in Hypertrophic Cardiomyopathy,” N. Engl. J. Med., vol. 342, no. 24, 2000, https://doi.org/10.1056/nejm200006153422403.
  • A. Barsheshet et al., “Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: Implications for mutation-specific response to β-blocker therapy in type 1 longQT syndrome,” Circulation, vol. 125, no. 16, 2012, https://doi.org/10.1161/CIRCULATIONAHA.111.048041.
  • A. J. Moss et al., “Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-gogo-related gene potassium channel,” Circulation, vol. 105, no. 7, 2002, https://doi.org/10.1161/hc0702.105124.
  • I. A. W. Van Rijsingen et al., “Risk factors for malignant ventricular arrhythmias in Lamin A/C mutation carriers: A European cohort study,” J. Am. Coll. Cardiol., vol. 59, no. 5, 2012, https://doi.org/10.1016/j.jacc.2011.08.078.
  • Amiodarone Trials Meta-Analysis Investigators, “Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials,” Lancet, vol. 350, no. 9089, 1997.
  • F. Boutitie et al., “Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators.,” Circulation, vol. 99, no. 17, pp. 2268-2275, May 1999, https://doi.org/10.1161/01.cir.99.17.2268.
  • W. A. Ray, K. T. Murray, S. Meredith, S. S. Narasimhulu, K. Hall, and C. M. Stein, “Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes,” N. Engl. J. Med., vol. 351, no. 11, 2004, https://doi.org/10.1056/nejmoa040582.
  • A. D. Mosholder, J. Mathew, J. J. Alexander, H. Smith, and S. Nambiar, “Cardiovascular Risks with Azithromycin and Other Antibacterial Drugs,” N. Engl. J. Med., vol. 368, no. 18, 2013, https://doi.org/10.1056/nejmp1302726.
  • L. Belardinelli, W. R. Giles, S. Rajamani, H. S. Karagueuzian, and J. C. Shryock, “Cardiac late Na+ current: proarrhythmic effects, roles in long QT syndromes, and pathological relationship to CaMKII and oxidative stress.,” Hear. Rhythm, vol. 12, no. 2, pp. 440-448, Feb. 2015, https://doi.org/10.1016/j.hrthm.2014.11.009.
  • G. Sarganas, E. Garbe, A. Klimpel, R. C. Hering, E. Bronder, and W. Haverkamp, “Epidemiology of symptomatic drug-induced long QT syndrome and torsade de pointes in Germany,” Europace, vol. 16, no. 1, 2014, https://doi.org/10.1093/europace/eut214.
  • “Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial Infarction,” N. Engl. J. Med., vol. 321, no. 6, pp. 406-412, Aug. 1989, https://doi.org/10.1056/NEJM198908103210629.
  • M. W. Deyell et al., “Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations,” Hear. Rhythm, vol. 9, no. 9, 2012, https://doi.org/10.1016/j.hrthm.2012.05.019.
  • T. S. Baman et al., “Relationship between burden of premature ventricular complexes and left ventricular function,” Hear. Rhythm, vol. 7, no. 7, 2010, https://doi.org/10.1016/j.hrthm.2010.03.036.
  • J. E. Ban et al., “Electrocardiographic and electrophysiological characteristics of premature ventricular complexes associated with left ventricular dysfunction in patients without structural heart disease,” Europace, vol. 15, no. 5, 2013, https://doi.org/10.1093/europace/eus371.
  • J. J. V. McMurray et al., “ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.,” Eur. Heart J., vol. 33, no. 14, 2012, https://doi.org/10.1093/eurheartj/ehs104.
  • S. J. Connolly et al., “Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.,” JAMA, vol. 295, no. 2, pp. 165-171, Jan. 2006, https://doi.org/10.1001/jama.295.2.165.
  • H. Calkins et al., “Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. Cooled RF Multi Center Investigators Group.,” J. Am. Coll. Cardiol., vol. 35, no. 7, 2000.
  • W. G. Stevenson et al., “Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction the multicenter thermocool ventricular tachycardia ablation trial,” Circulation, vol. 118, no. 25, 2008, https://doi.org/10.1161/CIRCULATIONAHA.108.788604.
  • H. Tanner et al., “Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: Results of the prospective multicenter Euro-VT-study,” J. Cardiovasc. Electrophysiol., vol. 21, no. 1, 2010, https://doi.org/10.1111/j.1540-8167.2009.01563.x.
  • J. A. Cairns, S. J. Connolly, R. Roberts, and M. Gent, “Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT,” Lancet, vol. 349, no. 9053, 1997, https://doi.org/10.1016/S0140-6736(96)08171-8.
  • D. G. Julian et al., “Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT,” Lancet, vol. 349, no. 9053, 1997, https://doi.org/10.1016/S0140-6736(96)09145-3.
  • D. S. Echt et al., “Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo: The Cardiac Arrhythmia Suppression Trial,” N. Engl. J. Med., vol. 324, no. 12, 1991, https://doi.org/10.1056/NEJM199103213241201.
  • J. G. F. Cleland et al., “The effect of cardiac resynchronization on morbidity and mortality in heart failure.,” N. Engl. J. Med., vol. 352, no. 15, pp. 1539-1549, Apr. 2005, https://doi.org/10.1056/NEJMoa050496.
  • S. A. Strickberger et al., “Amiodarone versus implantable cardioverterdefibrillator: Randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT,” J. Am. Coll. Cardiol., vol. 41, no. 10, 2003, https://doi.org/10.1016/S0735-1097(03)00297-3.
  • L. Køber et al., “Increased Mortality after Dronedarone Therapy for Severe Heart Failure,” N. Engl. J. Med., vol. 358, no. 25, 2008, https://doi.org/10.1056/nejmoa0800456.
  • S. J. Connolly et al., “Dronedarone in High-Risk Permanent Atrial Fibrillation,” N. Engl. J. Med., vol. 365, no. 24, 2011, https://doi.org/10.1056/nejmoa1109867.
  • J. Caceres et al., “Sustained bundle branch reentry as a mechanism of clinical tachycardia,” Circulation, vol. 79, no. 2, 1989, https://doi.org/10.1161/01.CIR.79.2.256.
  • P. Tchou, M. Jazayeri, S. Denker, J. Dongas, J. Caceres, and M. Akhtar, “Transcatheter electrical ablation of right bundle branch. A method of treating macroreentrant ventricular tachycardia attributed to bundle branch reentry,” Circulation, vol. 78, no. 2, 1988, https://doi.org/10.1161/01.CIR.78.2.246.
  • M. C. Kontos, D. B. Diercks, P. M. Ho, T. Y. Wang, A. Y. Chen, and M. T. Roe, “Treatment and outcomes in patients with myocardial infarction treated with acute β-blocker therapy: results from the American College of Cardiology’s NCDR(®).,” Am. Heart J., vol. 161, no. 5, pp. 864-870, May 2011, https://doi.org/10.1016/j.ahj.2011.01.006.
  • S. N. Singh et al., “Amiodarone in Patients with Congestive Heart Failure and Asymptomatic Ventricular Arrhythmia,” N. Engl. J. Med., vol. 333, no. 2, 1995, https://doi.org/10.1056/nejm199507133330201.
  • J. P. Piccini, J. S. Berger, and C. M. O’Connor, “Amiodarone for the prevention of sudden cardiac death: A meta-analysis of randomized controlled trials,” Eur. Heart J., vol. 30, no. 10, 2009, https://doi.org/10.1093/eurheartj/ehp100.
  • B. N. Singh et al., “Amiodarone versus Sotalol for Atrial Fibrillation,” N. Engl. J. Med., vol. 352, no. 18, 2005, https://doi.org/10.1056/nejmoa041705.
  • C. Lafuente-Lafuente, M. A. Longas-Tejero, J.-F. Bergmann, and J. Belmin, “Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation,” in Cochrane Database of Systematic Reviews, 2012. https://doi.org/10.1002/14651858.cd005049.pub3.
  • V. Kühlkamp, C. Mewis, J. Mermi, R. F. Bosch, and L. Seipel, “Suppression of sustained ventricular tachyarrhythmias: A comparison of d,l-sotalol with no antiarrhythmic drug treatment,” J. Am. Coll. Cardiol., vol. 33, no. 1, 1999, https://doi.org/10.1016/S0735-1097(98)00521-X.
  • A. L. Waldo et al., “Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction,” Lancet, vol. 348, no. 9019, 1996, https://doi.org/10.1016/S0140-6736(96)02149-6.
  • S. H. Hohnloser et al., “Effect of amiodarone and sotalol on ventricular defibrillation threshold: The Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) trial,” Circulation, vol. 114, no. 2, 2006, https://doi.org/10.1161/CIRCULATIONAHA.106.618421.
  • T. J. Bunch et al., “Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks,” PACE - Pacing Clin. Electrophysiol., vol. 34, no. 12, 2011, https://doi.org/10.1111/j.1540-8159.2011.03208.x.
  • A. Pacifico et al., “Prevention of Implantable-Defibrillator Shocks by Treatment with Sotalol,” N. Engl. J. Med., vol. 340, no. 24, 1999, https://doi.org/10.1056/nejm199906173402402.
  • A. Goyal et al., “Serum potassium levels and mortality in acute myocardial infarction,” JAMA - J. Am. Med. Assoc., vol. 307, no. 2, 2012, https://doi.org/10.1001/jama.2011.1967.
  • A. B. de Luna, P. Coumel, and J. F. Leclercq, “Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases,” Am. Heart J., vol. 117, no. 1, 1989, https://doi.org/10.1016/0002-8703(89)90670-4.
  • C. M. Albert et al., “Prospective study of sudden cardiac death among women in the United States,” Circulation, vol. 107, no. 16, 2003, https://doi.org/10.1161/01.CIR.0000065223.21530.11.
  • T. Smith, L. Jordaens, D. A. M. J. Theuns, P. F. Van Dessel, A. A. Wilde, and M. G. Myriam Hunink, “The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: A European analysis,” Eur. Heart J., vol. 34, no. 3, 2013, https://doi.org/10.1093/eurheartj/ehs090.
  • J. M. Garnreiter, T. A. Pilcher, S. P. Etheridge, and E. V. Saarel, “Inappropriate ICD shocks in pediatrics and congenital heart disease patients: Risk factors and programming strategies,” Hear. Rhythm, vol. 12, no. 5, 2015, https://doi.org/10.1016/j.hrthm.2015.01.028.
  • D. P. Zipes, “A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators,” N Engl J Med, vol. 337, no. 22, 1997.
  • S. J. Connolly et al., “Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone,” Circulation, vol. 101, no. 11, 2000, https://doi.org/10.1161/01.CIR.101.11.1297.
  • K. H. Kuck, R. Cappato, J. Siebels, and R. Rüppel, “Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The cardiac arrest study hamburg (CASH),” Circulation, vol. 102, no. 7, 2000, https://doi.org/10.1161/01.CIR.102.7.748.
  • S. J. Connolly et al., “Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.,” Eur. Heart J., vol. 21, no. 24, 2000.
  • M. H. Raitt et al., “‘Stable’ ventricular tachycardia is not a benign rhythm: Insights from the Antiarrhythmics Versus Implantable Defibrillators (AVID) Registry,” Circulation, vol. 103, no. 2, 2001, https://doi.org/10.1161/01.CIR.103.2.244.
  • J. T. Bigger Jr., “Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators,” N Engl J Med, vol. 337, no. 22, 1997.
  • M. Block and G. Breithardt, “The implantable cardioverter defibrillator and primary prevention of sudden death: The multicenter automatic defibrillator implantation trial and the coronary artery bypass graft (CABG)-patch trial,” in American Journal of Cardiology, 1999, vol. 83, no. 5 B. https://doi.org/10.1016/S0002-9149(98)01028-5.
  • “Multicenter Automatic Defibrillator Implantation Trial (MADIT): Design and Clinical Protocol,” Pacing Clin. Electrophysiol., vol. 14, no. 5, 1991, https://doi.org/10.1111/j.1540-8159.1991.tb04136.x.
  • I. Goldenberg et al., “Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.,” J. Am. Coll. Cardiol., vol. 47, no. 9, pp. 1811-1817, May 2006, https://doi.org/10.1016/j.jacc.2005.12.048.
  • D. L. Packer et al., “Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: Analysis from the sudden cardiac death in heart failure trial,” Circulation, vol. 120, no. 22, 2009, https://doi.org/10.1161/CIRCULATIONAHA.109.853689.
  • A. Kadish et al., “Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators*,” N. Engl. J. Med., vol. 350, no. 21, 2004.
  • D. Erkapic et al., “Long-term benefit of implantable cardioverter/ defibrillator therapy after elective device replacement: Results of the INcidence free SUrvival after ICD REplacement (INSURE) trial-a prospective multicentre study,” Eur. Heart J., vol. 34, no. 2, 2013, https://doi.org/10.1093/eurheartj/ehs177.
  • V. Kini et al., “Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: Are indications still met?,” J. Am. Coll. Cardiol., vol. 63, no. 22, 2014, https://doi.org/10.1016/j.jacc.2014.03.025.
Еще
Статья научная
SciUp 2024 © 2024 ©